Literature DB >> 17072232

Management strategies for brittle diabetes.

M-C Vantyghem1, M Press.   

Abstract

Type 1 diabetes is an intrinsically unstable condition. However, the term "brittle diabetes" is reserved for those cases in which the instability, whatever its cause, results in disruption of life and often recurrent and/or prolonged hospitalization. It affects 3/1000 insulin-dependent diabetic patients, mainly young women. Its prognosis is poor with lower quality of life scores, more microvascular and pregnancy complications and shortened life expectancy. Three forms have been described: recurrent diabetic ketoacidosis, predominant hypoglycemic forms and mixed instability. Main causes of brittleness include malabsorption, certain drugs (alcohol, antipsychotics), defective insulin absorption or degradation, defect of hyperglycemic hormones especially glucocorticoid and glucagon, and above all delayed gastric emptying as a result of autonomic neuropathy. Psychosocial factors are very important and factitious brittleness may lead to a self-perpetuating condition. The assessment of brittle diabetes requires quantification of the variability of blood glucose levels. To quantify instability, measures which have been developed, include Mean Amplitude of the largest Glycemic Excursions (MAGE), Mean Of Daily Differences (MODD), Lability Index (LI), Low Blood Glucose Index (LBGI), Clarke's score, Hyposcore, and continuous blood glucose monitoring. Once psychogenic problems have been excluded, therapeutic strategies require firstly, the treatment of underlying organic causes of the brittleness whenever possible and secondly optimising standard insulin therapy using analogues, multiple injections and consideration of Continuous Subcutaneous Insulin Infusion. Alternative approaches may still be needed for the most severely affected patients. Isolated islet transplantation (IIT), which restores glucose sensing, should be considered in cases of hypoglycaemic unawareness and/or lability especially if the body mass index is < 25, but with current immunosuppressive protocols patients must have normal renal function and preferably no plans for pregnancy. Implantable pumps have advantages for patients who either weigh more than 80 kgs or have abnormalities of kidney or liver function or are highly sensitised.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072232     DOI: 10.1016/s0003-4266(06)72600-2

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  7 in total

Review 1.  Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia.

Authors:  Ajay V Maker; Raashid Sheikh; Vinita Bhagia
Journal:  Langenbecks Arch Surg       Date:  2017-07-21       Impact factor: 3.445

2.  Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3).

Authors:  Marie-Christine Vantyghem; Violeta Raverdy; Anne-Sophie Balavoine; Frédérique Defrance; Robert Caiazzo; Laurent Arnalsteen; Valéry Gmyr; Marc Hazzan; Christian Noël; Julie Kerr-Conte; Francois Pattou
Journal:  J Clin Endocrinol Metab       Date:  2012-09-20       Impact factor: 5.958

3.  Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study.

Authors:  Ronan Roussel; Jean-Pierre Riveline; Eric Vicaut; Gérard de Pouvourville; Bruno Detournay; Corinne Emery; Fleur Levrat-Guillen; Bruno Guerci
Journal:  Diabetes Care       Date:  2021-04-20       Impact factor: 17.152

4.  Australian Nurse Practitioner Practice: Value Adding through Clinical Reflexivity.

Authors:  Michelle Woods; Giuliana Murfet
Journal:  Nurs Res Pract       Date:  2015-01-29

5.  Importance of insulin immunoassays in the diagnosis of factitious hypoglycemia.

Authors:  Özlem Nalbantoğlu Elmas; Korcan Demir; Nusret Soylu; Nilüfer Çelik; Behzat Özkan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2014-12

6.  Implanting 1.1B4 human β-cell pseudoislets improves glycaemic control in diabetic severe combined immune deficient mice.

Authors:  Alastair D Green; Srividya Vasu; Neville H McClenaghan; Peter R Flatt
Journal:  World J Diabetes       Date:  2016-11-15

Review 7.  Monitoring with In Vivo Electrochemical Sensors: Navigating the Complexities of Blood and Tissue Reactivity.

Authors:  Pankaj Vadgama
Journal:  Sensors (Basel)       Date:  2020-06-02       Impact factor: 3.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.